LOG IN
SIGN UP
MARKET
COLL
COLL
Collegium Pharmaceutical Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
15.94
+0.40
+2.57%
After Hours: 15.94 0 0.00% 16:01 05/27 EDT
OPEN
15.68
PREV CLOSE
15.54
HIGH
15.97
LOW
15.50
VOLUME
301.06K
TURNOVER
0
52 WEEK HIGH
25.66
52 WEEK LOW
14.04
MARKET CAP
541.53M
P/E (TTM)
17.23
1D
5D
1M
3M
1Y
5Y
Collegium to Participate in H.C. Wainwright Global Investment Conference
STOUGHTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will present at the H.C. Wainwright Global Investment Conference bein...
GlobeNewswire · 05/17 12:00
How Good Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL), When It Comes To ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Simply Wall St. · 05/16 14:47
Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:55
Recap: Collegium Pharmaceutical Q1 Earnings
Collegium Pharmaceutical (NASDAQ:COLL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/10 21:02
Collegium Pharmaceutical GAAP EPS of -$0.39, revenue of $83.75M
Collegium Pharmaceutical press release (NASDAQ:COLL): Q1 GAAP EPS of -$0.39. Revenue of $83.75M (-4.5% Y/Y). 2022 Guidance: Total product revenues are expected in the range of $450.0 million to $465.0 million,
Seekingalpha · 05/10 20:29
BRIEF-Collegium Reports First Quarter 2022 Financial Results
reuters.com · 05/10 20:09
Collegium Pharmaceutical Q1 EPS $(0.39) Down From $0.41 YoY, Sales $83.80M Beat $78.88M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly losses of $(0.39) per share. This is a 195.12 percent decrease over earnings of $0.41 per share from the same period last year. The company reported quarterly
Benzinga · 05/10 20:06
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
No Data
Learn about the latest financial forecast of COLL. Analyze the recent business situations of Collegium Pharmaceutical Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 8 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
25.00%Strong Buy
62.50%Buy
0.00%Hold
12.50%Under-perform
0.00%Sell
Analyst Price Target
The average COLL stock price target is 28.86 with a high estimate of 37.00 and a low estimate of 8.00.
Current 15.94
EPS
Actual
Estimate
-0.030.450.931.41
Institutional Holdings
Institutions: 256
Institutional Holdings: 39.17M
% Owned: 115.31%
Shares Outstanding: 33.97M
TypeInstitutionsShares
Increased
62
1.90M
New
29
944.03K
Decreased
53
2.21M
Sold Out
13
296.44K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Director
Michael Heffernan
President/Chief Executive Officer/Director
Joseph Ciaffoni
Chief Financial Officer/Executive Vice President
Colleen Tupper
Executive Vice President/Chief Administrative Officer/General Counsel/Secretary
Shirley Kuhlmann
Executive Vice President
Scott Dreyer
Executive Vice President
Thomas Smith
Lead Director/Independent Director
Gino Santini
Independent Director
Rita Balice-Gordon
Independent Director
Garen Bohlin
Independent Director
John Fallon
Independent Director
John Freund
Independent Director
Neil Mcfarlane
Independent Director
Gwen Melincoff
No Data
No Data
About COLL
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on pain management. The Company's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone, and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate in adults.
Webull offers kinds of Collegium Pharmaceutical Inc stock information, including NASDAQ:COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.